ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1629 • 2014 ACR/ARHP Annual Meeting

    Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus

    Johannes Schulte-Pelkum1, Diana Carmona-Fernandes2, Maria Jose Santos2, Roger Albesa1 and Michael Mahler1, 1Research, INOVA Diagnostics, San Diego, CA, 2Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

    Background/Purpose Anti-dsDNA antibodies (aab) are known as important serological marker to aid in the diagnosis of systemic lupus erythematosus (SLE) and are part of the…
  • Abstract Number: 1628 • 2014 ACR/ARHP Annual Meeting

    Upregulation of Myxovirus Resistance Protein 1 in Patients with Neuropsychiatric Systemic Lupus Erythematosus

    Yuka Shimizu, Shinsuke Yasuda, Takashi Kurita, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Toshiyuki Watanabe, Michihito Kono, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Background/Purpose: Nervous system disease is one of the most common manifestations in patients with systemic lupus erythematosus (SLE) that significantly affects morbidity and mortality. Due…
  • Abstract Number: 1627 • 2014 ACR/ARHP Annual Meeting

    The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies

    Savino Sciascia1, Giovanni Sanna2, Veronica Murru3, Dario Roccatello4, Munther A. Khamashta5 and Maria Laura Bertolaccini3, 112 Kennington Ave, Rayne Institute, St. Thomas Hospital, London, United Kingdom, 2Lupus Unit, St. Thomas' Hospital, London, United Kingdom, 3Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 4CORSO RAFFAELLO 30, UNIVERSITY OF TURIN (ITALY), TURIN, Italy, 5Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

    Background/Purpose: Arterial event are frequent in the antiphospholipid syndrome (APS) and stroke is a major clinical manifestation of syndrome. Recently, we conducted a study in…
  • Abstract Number: 1626 • 2014 ACR/ARHP Annual Meeting

    Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE

    Fleur Schaper1, Gerda Horst1, Daan van Beijeren Bergen en Henegouwen1, Johan Bijzet1, Karina de Leeuw1, Alja Stel1, Pieter C Limburg2, Peter Heeringa3 and Johanna Westra1, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, 3Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: High mobility group box 1 (HMGB1) is a damage-associated molecular pattern and can be divided in three separate domains: the A Box, B Box…
  • Abstract Number: 1625 • 2014 ACR/ARHP Annual Meeting

    Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles

    Kimberly Carroll1, Elizabeth Mitton-Fitzgerald1, Brittany Bettendorf2, Claudia Gohr1, Mary E. Cronin1 and Ann K. Rosenthal3, 1Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 2Internal Medicine/Pediatrics, Medical College of Wisconsin, Wauwatosa, WI, 3Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Microparticles (MPs) are circulating membrane-bound vesicles derived from blood and endothelial cells via a highly regulated process. They are immunomodulatory and have been implicated…
  • Abstract Number: 1624 • 2014 ACR/ARHP Annual Meeting

    The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE

    Eoghan M. McCarthy1, Joan Ní Gabhann2, Siobhán Smith2, Michele Doran3, Gaye Cunnane4, S. Donnelly5, Donough Howard1, Paul G. O'Connell1, Caroline Jefferies2 and Grainne M. Kearns6, 1Rheumatology, Beaumont Hospital, Dublin, Ireland, 2Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, 3Rheumatology, St. James's Hospital, Dublin, Ireland, 4Dept of Rheumatology, St James's Hospital and Trinity College Dublin, Dublin, Ireland, 5Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 6Rheumatology Department, Beaumont Hospital, Dublin, Ireland

    Background/Purpose Monocytes are increasingly recognised to play a key role in the pathogenesis of SLE. Different subpopulations of monocytes contribute to the disease through dysregulated pro…
  • Abstract Number: 1623 • 2014 ACR/ARHP Annual Meeting

    Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus

    Julie Ducreux1, Séverine Nieuwland2, Frédéric A. Houssiau1 and Bernard R. Lauwerys1, 1Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 2Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: systemic lupus erythematosus (SLE) is characterized by a break of tolerance to autoantigens, and polyclonal activation of B cells. We performed multicolor flow cytometry…
  • Abstract Number: 1642 • 2014 ACR/ARHP Annual Meeting

    A Prospective Study of Vitamin D Effects on T Cells Phenotype in Patients with Systemic Lupus Erythematosus Treated with Different Regimens of Supplementation for Two Years

    Silvia Piantoni, Laura Andreoli, Alessandra Zanola, Francesca Dall'Ara, Mirko Scarsi and Angela Tincani, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy

    Background/Purpose Vitamin D (VD) receptor is constitutively expressed on the membrane of multiple cells, including lymphocytes. Recent studies highlight that VD may have an action…
  • Abstract Number: 1641 • 2014 ACR/ARHP Annual Meeting

    Baseline Factors That Predict High BLyS Levels in Patients with Systemic Lupus Erythematosus (SLE) and High Disease Activity

    David Roth1, April Thompson2, Tom Tang2, Anne Hammer2 and Charles T. Molta1, 1GlaxoSmithKline, Philadelphia, PA, 2GlaxoSmithKline, Research Triangle Park, NC

    Background/Purpose: Post hoc analyses from the BLISS trials demonstrated that patients with high baseline B-lymphocyte stimulator (BLyS) levels (≥2 ng/ml) had an increased risk of…
  • Abstract Number: 1640 • 2014 ACR/ARHP Annual Meeting

    Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus

    Yuko Okamoto1, Yasuhiro Katsumata1, Yasushi Kawaguchi1, Manabu Kawamoto1, Takahisa Gono1, Masanori Hanaoka1, Tomoaki Higuchi1, Hidenaga Kawasumi1 and Hisashi Yamanaka2, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose . B cell activating factor of tumor necrosis factor family (BAFF) is a positive regulator of B cell function and expressed in dendritic cells,…
  • Abstract Number: 1639 • 2014 ACR/ARHP Annual Meeting

    Serum Anti-Müllerian Hormone Levels in SLE Patients. the Disease Severity and Cyclophosphamide Reduce the Ovarian Reserve

    Gerardo Marino1, Laura Messuti1, Maria Rita Gigante1, Angela Barini2, Silvia Canestri1, Antonella Barini2, Barbara Tolusso1, Elisa Gremese1 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 2Department of Laboratory Medicine, Institute of Biochemistry and Clinical Biochemistry, Catholic University of The Sacred Heart, Rome, Italy

    Background/Purpose . Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age, can lead to severe organ involvement and may require prolonged immunosuppressive therapy. Anti-Müllerian Hormone is produced by the granulosa ovary cells and…
  • Abstract Number: 1638 • 2014 ACR/ARHP Annual Meeting

    Anti-Dense Fine Speckled 70 Antibodies:  Long-Term Followup Study of Clinical Associations in a US Laboratory Patient Population

    Mark H. Wener1 and Kathleen Hutchinson2, 1Rheumatology & Lab Med, University of Washington, Seattle, WA, 2Lab Medicine, University of Washington, SEATTLE, WA

    Background/Purpose The recently recognized nuclear dense fine speckled immunofluorescence (IF) ANA pattern is associated with antibodies to the dense fine speckled 70 (DFS70) antigen.   Presence…
  • Abstract Number: 1637 • 2014 ACR/ARHP Annual Meeting

    LACK of Association of ANTI CCP and Arthritis in SLE

    Adrian Pablo Salas1, Mariana Alejandra Pera2, Pierina Sansinanea2, Mercedes Argentina García2, Valeria Arturi2, Ana Carolina Costi2, Claudia Elizabeth Pena2, Adriana Testi3, Josefina Marcos4 and Ariel Vulcano1, 1Rheumatology Unit, HIGA San Martin, La Plata, Argentina, 2Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, 3Rheumatology Unit, HIGA San Martin, La Plata - Buenos Ai, Argentina, 4HIGA San Martín, La Plata, Argentina

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by multiplicity of auto antibodies, many of them play an unknown role in disease pathogenesis. Anti cyclic citrulinated…
  • Abstract Number: 1616 • 2014 ACR/ARHP Annual Meeting

    Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling

    Rachael Hawtin1, Wouter Korver2, Erik Evensen2, Diane Longo2, Drew Hotson2, Nikil Wale2, Andy Conroy2, Alessandra Cesano2, Barbara Mittleman2, Shirley Tu2, Matt Westfall2, Tsung Lin3, Vik Rao4, Elena Peeva5, Stephen Benoit5, Martin Hodge3, James D. Clark3, Jean-Baptiste Telliez3 and Aaron R. Winkler4, 1Nodality Inc., South San Francisco, CA, 2Nodality, Inc., South San Francisco, CA, 3Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, 4Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA, 5Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA

    Background/Purpose:   Systemic Lupus Erythematosus (SLE) is a multi-system rheumatic disease with widely differing clinical manifestations and outcomes. Treatment is generally immunosuppressive, with no available…
  • Abstract Number: 1615 • 2014 ACR/ARHP Annual Meeting

    MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE

    Bo Qu1,2, Xiao Han2 and Nan Shen1,2,3, 1Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, 2Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, 3The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH

    Background/Purpose Type I interferon(IFN) is a critical pathogenic factor in Systemic Lupus Erythematosus(SLE) and its associated nephritis, as elevated IFN inducible genes have been found…
  • « Previous Page
  • 1
  • …
  • 1941
  • 1942
  • 1943
  • 1944
  • 1945
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology